Citius Oncology has secured up to $36.5m to accelerate the commercialisation of Lymphir, a recombinant fusion protein immune therapy.

MSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML).

Why does product loss occur in aseptic fill-finish, and how can a CDMO overcome material constraints to preserve as much drug product as possible?

As with its previous siRNA deal, Madrigal plans to explore whether gene-silencing could complement its lead drug Rezdiffra.

Latus Bio has closed a $97m Series A financing round to expand the reach of its gene therapies targeting wider patient groups.

Non-viral gene therapies may hold potential to overcome some safety, pricing and manufacturing hurdles linked to viral alternatives.

UCB’s Candid acquisition marks its second foray into the TCE space – closely following a $1.1bn licensing deal with TCE specialist, Antengene.

Novo Nordisk is set to launch Ozempic, its oral GLP-1 receptor agonist pill for adults with type 2 diabetes, in the US.

BMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year.

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.

Arrowhead Pharmaceuticals has received approval from the Australian TGA for Redemplo to treat familial chylomicronemia syndrome.